Imatinib Normon (Imatinib)

Imatinib binds to the ATP‑binding pocket of specific tyrosine kinases—BCR‑ABL, c‑KIT and PDGFR—preventing their activation. This blocks downstream signaling pathways that drive cell proliferation and survival, leading to reduced tumor growth and induction of programmed cell death in malignant cells.

The prescribed dose of Imatinib Normon is individualized by the treating physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and response to therapy. No fixed regimen is provided here; dosing decisions are made by qualified healthcare professionals.

Data on imatinib use in pregnancy and lactation are limited, and the drug may pose risks to the fetus or infant. It is generally avoided unless the potential therapeutic benefit justifies the potential harm. Women of child‑bearing potential should discuss contraception and risk‑benefit considerations with their clinician.

To request Imatinib Normon, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib was the first targeted therapy for CML and remains a standard first‑line option. Second‑generation tyrosine kinase inhibitors such as dasatinib and nilotinib offer higher potency and may be preferred in cases of resistance or intolerance. Choice of therapy depends on disease risk, mutation profile, comorbidities and physician judgment.

Imatinib Normon should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct light, and avoid storing in humid or excessively hot environments to maintain product stability.

Imatinib Normon is taken orally as a whole tablet with a glass of water. It can be administered with or without food, but patients should follow any specific instructions from their prescriber. Swallow the tablet whole; do not crush, chew, or split unless directed by a healthcare professional.

Serious adverse events include hepatotoxicity (elevated liver enzymes or liver injury), cardiotoxicity such as congestive heart failure, and severe neutropenia that can predispose to infections. Patients should be monitored regularly for liver function, cardiac status and complete blood counts, and any concerning symptoms reported promptly.

Imatinib Normon is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Patients with severe hepatic impairment, uncontrolled heart failure, or those receiving certain strong CYP3A4 inducers or inhibitors that cannot be managed should avoid the drug. Clinical judgment is required for each case.